Replies to post #32360 on Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Thank You, looking forward to any info your further post.

[GMA13]

Thanks for your update. I free with your conclusions,
MRKR should issue a PR to set the record accurately, i.e. Q4 versus Q3.

[GMA13]

The following below in italic font is a copy of Peter Hoang’s response to portions of my email to Peter’s attention.

My 1st Name,

Those milestones you refer to were previously met, other than the update we have later this year for patients who have been treated with product manufactured using the new manufacturing process:

I. November 10, 2021: Q3 2021 Update PR
“Topline readout of Group 2 active disease anticipated in Q1 2022

Done in end of Q1 update (6 patients in the safety lead-in). 5 Frank relapse patients, no responses. 1 MRD+ patient converted to CR MRD-

II. March 17, 2022: YE 2021 Update PR
“Topline readout of Group 2 active disease anticipated in Q2 2022”

Done in end of Q2 update (7 patients in Phase II): 6 frank relapse, no responses, 1 MRD+ patient converted to CR MRD-

III. May 13, 2022: Q1 2022 Update PR
“Topline readout of Group 2 active disease is anticipated in Q2 2022”

See II above, as this refers to the same milestone

IV. August 11, 2022: Q2 2022 Update PR
“We are proud of our progress this year in advancing our Company-sponsored clinical program in AML, and early results support the ability of MT-401, a multiTAA-specific T cell product, to drive results for patients with AML,”
and
“We expect to provide a topline readout of active disease patients in Q3 2022”

We expect to read out the first 6 patients treated with the new process at 200mm cells at year end

[Lady_luck]

Are we to assume that there was another “error” in the verbiage?